



APPENDIX 4C

Quarter Ended 31 March 2025

Chimeric Therapeutics Limited

ACN 638 835 828

ASX: CHM

For personal use only

QUARTERLY ACTIVITIES REPORT FOR THE PERIOD ENDING 31 MARCH 2025

Melbourne, Australia, 23 April 2025: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to provide a summary of its activities for the quarter ended 31 March 2025.

- CHM CDH17 CAR-T trial is progressing as it recruits 7 patients, 4 dosed, 1 pending dosing and 2 pending manufacturing.
- CHM CORE-NK Frontline study has progressed to recruit two patients; one dosed at MD Anderson Cancer Centre in Houston, Texas.
- CHM CORE-NK Combination trial has continued at Case Western University with four patients dosed, one complete response at 28 days in a patient with blood cancer.
- CHM CLTX GBM trial remains open in Austin, Texas.
- \$4.0m non-dilutive was received from a U.S. Family office to support the development of CHM CDH17 in the Phase 1/2 clinical trial.

Clinical Trial Updates

UCHICAGO MEDICINE JOINS CHM CDH17 PHASE 1/2 CLINICAL TRIAL

In February, the Company announced that the University of Chicago Medicine (UChicago Medicine) joined its ongoing Phase 1/2 clinical trial for the novel CHM CDH17 CAR-T cell therapy. The trial targets advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumours.

UChicago Medicine, a renowned cancer treatment and research center, joins existing trial sites including Sarah Cannon and the University of Pennsylvania. Associate Professor Dan Olson will lead the trial site at UChicago, supported by Chimeric’s Scientific Advisory Board member Professor Michael Bishop, a globally recognised pioneer in cancer therapies.

CHM CDH17 is the world’s first anti-CDH17-directed CAR-T therapy and has demonstrated strong preclinical evidence, including complete eradication of tumours in multiple cancer types. The Phase 1 segment aims to enrol up to 15 patients to determine safety and optimal dosage, with four patients dosed and five successful manufacturing runs completed thus far.

For personal use only



US PATENT ALLOWED FOR CHM CDH17 TECHNOLOGY

In March, the US Patent and Trademark Office (USPTO) allowed the issuance of a patent covering Chimeric's proprietary CHM CDH17 CAR-T technology. This technology is a third-generation CAR-T therapy specifically targeting CDH17, a protein highly expressed in gastrointestinal cancers and linked to poor prognosis and metastatic disease.

The allowed US patent application, titled "Compositions and Methods for Retrieving Tumor-related Antibodies and Antigens," is expected to grant intellectual property protection through to at least 2039. This strengthens Chimeric's global commercial position and intellectual property portfolio significantly.

Chimeric holds exclusive worldwide development and commercialization rights for CHM CDH17 CAR-T, currently undergoing a Phase 1/2 clinical trial at prominent US institutions, including Sarah Cannon Research Institute, University of Pennsylvania, and UChicago Medicine. Preclinical data published previously in Nature Cancer demonstrated the potential of CHM CDH17 CAR-T to eradicate multiple types of tumors while sparing healthy tissue.

Financial

An Appendix 4C Quarterly Cash Flow report is attached to this announcement.

As detailed in the attached ASX Appendix 4C the Company had \$5.06 million in cash and cash equivalents at 31 March 2025, decreasing from \$5.07 million at the end of the prior quarter.

During the quarter, the company received \$3.97 million in non-dilutionary funding, which helped support its operating activities. The net cash inflow in Operating Activities during the quarter was \$0.03 million with 88% of operating activities relates to staff costs and research and development as detailed in the Appendix 4C.

The net financing outflows for the quarter was \$0.06 million which consists of transaction costs related to the issue of equity.

In accordance with Listing Rule 4.7C, payments made to related parties and their associated included in items 6.1 of the Appendix 4C include payments for remuneration of director fees to executive and non-executive directors in the normal course of business at commercial rates, excluding reimbursements of out-of-pocket expenses. The Board has focused on prudent management of cash and as a result careful cost cutting strategy projected total expenditure has and will continue to be reduced.

For personal use only



\$4.0m Non-Dilutionary Funding from US-based family office

Chimeric secured approximately A\$4.0 million (US\$2.5 million) in non-dilutionary funding from an undisclosed US-based philanthropic family office. The funding supports the continued development of the company's innovative CHM CDH17 CAR-T cell therapy, currently being studied in a Phase 1/2 clinical trial targeting advanced colorectal, gastric, and intestinal neuroendocrine cancers.

The funding is provided without any obligation to issue equity or transfer intellectual property, offering a substantial financial benefit without dilution for existing shareholders.

Chimeric Therapeutics views this funding as strong validation of the CHM CDH17 program and will use these funds to accelerate clinical development without impacting shareholder equity.

Entitlement Offer to raise approximately \$3.2 million

In March, Chimeric announced a non-renounceable entitlement offer aimed at raising approximately \$3.2 million from eligible shareholders. Under this offer, shareholders were given the opportunity to subscribe for two new shares for every five shares they currently hold, at a price of \$0.005 per new share.

For each new share subscribed, shareholders received one free attaching option exercisable at \$0.008, expiring on 19 December 2025. The entitlement offer includes a top-up facility allowing shareholders who fully subscribe their entitlements to apply for additional shares from the shortfall, if available. Chimeric also reserves the right to place any remaining shortfall within three months after the closing date of the offer.

Funds raised through this offer will primarily support the progression of Chimeric's CHM CDH17 Phase 1/2 CAR-T clinical trial, targeting advanced gastrointestinal cancers, as well as the continued development of the CHM CORE-NK clinical programs in collaboration with institutions such as Case Western University and MD Anderson Cancer Centre. Additionally, the funds will be allocated to general working capital and covering costs associated with the capital raising.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR-T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed

For personal use only



across multiple different disease areas in oncology with 4 clinical stage programs.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR-T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR-T was published by Dr. Hua and colleagues in 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CLTX is a novel and promising CAR-T therapy developed for the treatment of patients with solid tumours. CLTX CAR-T is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

Authorised on behalf of the Chimeric Therapeutics board of directors by Executive Chairman Paul Hopper.

Contact

Investors

Dr Rebecca McQualter

Chief Executive Officer

Chimeric Therapeutics

E: investors@chimerictherapeutics.com

W: www.chimerictherapeutics.com

Media

Matthew Wright

NWR Communications

T: +61 451 896 420

E: matt@nwrcommunications.com.au

For personal use only

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Chimeric Therapeutics Limited

ABN

68 638 835 828

Quarter ended ("current quarter")

31 March 2025

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers (inclusive of GST)	3,969	3,969
1.2 Payments for (inclusive of GST)		
(a) research and development	(2,735)	(5,478)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs*	(747)	(3,768)
(f) administration and corporate costs	(549)	(1,671)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	16	42
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	4,172
1.8 Other (provide details if material)	73	155
1.9 Net cash from / (used in) operating activities	27	(2,579)

*Staff costs includes staff, directors, scientific advisors and employment related costs.

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
2.	Cash flows from investing activities		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	-	-
3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	5,000
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(63)	(388)
3.5	Proceeds from borrowings	-	1,562
3.6	Repayment of borrowings	-	(1,562)
3.7	Transaction costs related to loans and borrowings	-	(86)
3.8	Dividends paid	-	-
3.9	Other – payments of licence fee liabilities	-	-
3.10	Net cash from / (used in) financing activities	(63)	4,526

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	5,068	3,053
4.2	Net cash from / (used in) operating activities (item 1.9 above)	27	(2,579)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(63)	4,526
4.5	Effect of movement in exchange rates on cash held	27	59
4.6	Cash and cash equivalents at end of period	5,059	5,059

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	5,059	5,068
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	5,059	5,068

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	25
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

Item 6.1 – Include payments for remuneration of director fees to executive and non-executive directors in the normal course of business at commercial rates, excluding reimbursements of out-of-pocket expenses.

7. Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	-	-
7.5 Unused financing facilities available at quarter end		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (item 1.9)	27
8.2 Cash and cash equivalents at quarter end (item 4.6)	5,059
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	5,059
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	N/A
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: <ul style="list-style-type: none"> The Company does not expect to maintain the current level of net operating cash flows as the Company received a \$4m non-dilutionary funds for the development of CHM CDH17 CAR-T during the March 2025 quarter. 	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: <ul style="list-style-type: none"> N/A 	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer: <ul style="list-style-type: none"> N/A 	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 23 April 2025

Authorised by: The Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

For personal use only



CHIMERIC
THERAPEUTICS

☎ +61 3 9824 5254

✉ info@chimerictherapeutics.com

Chimeric Therapeutics Limited

ACN 638 835 828

ASX: CHM